Skip to content
Markets News
Stocks1 min read

Wegovy cuts BMI in children ages 6 to under 12 in trial

Makkler Newsroom
November 16, 2026 · Based on reporting by CNBC

Novo Nordisk reported lower BMI after 68 weeks of Wegovy treatment, while saying longer-term effects in children remain unknown.

Key takeaways

  • Wegovy lowered BMI by an estimated 19.7 percentage points versus placebo at 68 weeks among children who stayed on treatment.
  • Novo reported no safety concerns related to growth or pubertal development in the trial.

Novo Nordisk said Wegovy lowered body mass index in children ages 6 to under 12 with obesity in a late-stage trial. At 68 weeks, BMI fell 17.4% among children who stayed on the drug and rose 2.2% among those on placebo.

The estimated average difference between the groups was 19.7 percentage points. Across all 167 children, including those who stopped treatment, Wegovy lowered BMI by an estimated 16.2 percentage points more than placebo.

All participants also received lifestyle changes, including a reduced-calorie diet and increased physical activity. Novo said the drug’s safety and tolerability were consistent with adult trials, with no observed safety concerns related to growth or pubertal development.

The study does not establish whether treating obesity earlier changes its long-term course, Novo medical director Andrea Traina said, calling this an “evidence gap.”

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.